The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis
| العنوان: | The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis |
|---|---|
| المؤلفون: | Peter J. K. Kuppen, Antien L. Mooyaart, Ronald van Eijk, Anton J. M. de Craen, Judith R. Kroep, Cornelis J.H. van de Velde, Esther Bastiaannet, C.C. Engels, Gerrit-Jan Liefers, M. Kiderlen, Vincent T.H.B.M. Smit |
| المصدر: | Breast Cancer Research and Treatment Breast Cancer Research and Treatment, 156(2), 361-370 |
| بيانات النشر: | Springer Science and Business Media LLC, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Receptor, ErbB-2, Epidemiology, Population, Breast Neoplasms, medicine.disease_cause, Phosphatidylinositol 3-Kinases, Prognostic markers, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, education, Survival analysis, Aged, Netherlands, Aged, 80 and over, Mutation, education.field_of_study, Relative survival, business.industry, PIK3CA, Competing risk, Prognosis, medicine.disease, Survival Analysis, Up-Regulation, Gene Expression Regulation, Neoplastic, Geriatric oncology, HER-2, Anti-HER2 therapy, 030220 oncology & carcinogenesis, Female, business |
| الوصف: | Studies to confirm the effect of acknowledged prognostic markers in older breast cancer patients are scarce. The aim of this study was to evaluate the prognostic value of HER-2 overexpression and PIK3CA mutations in older breast cancer patients. Female breast cancer patients aged 65 years or older, diagnosed between 1997 and 2004 in a geographical region in The Netherlands, with an invasive, non-metastatic tumour and tumour material available, were included in the study. The primary endpoint was relapse-free period and secondary endpoint was relative survival. Determinants were immunochemical HER-2 scores (0/1+, 2+ or 3+) and PIK3CA as a binary measure. Overall, 1698 patients were included, and 103 had a HER-2 score of 3+. HER-2 overexpression was associated with a higher recurrence risk (5 years recurrence risk 34 % vs. 12 %, adjusted p = 0.005), and a worse relative survival (10 years relative survival 48 % vs. 84 % for HER-2 negative; p = 0.004). PIK3CA mutations had no significant prognostic effect. We showed, in older breast cancer patients, that HER-2 overexpression was significantly associated with a worse outcome, but PIK3CA mutations had no prognostic effect. These results imply that older patients with HER-2 overexpressing breast cancer might benefit from additional targeted anti-HER-2 therapy. Electronic supplementary material The online version of this article (doi:10.1007/s10549-016-3734-y) contains supplementary material, which is available to authorised users. |
| تدمد: | 1573-7217 0167-6806 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c76a6cb4477d9666b59f6b1efe8051Test https://doi.org/10.1007/s10549-016-3734-yTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....00c76a6cb4477d9666b59f6b1efe8051 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15737217 01676806 |
|---|